Debiopharm & BIOASTER join forces to expand research to combat infectious diseases.
Debiopharm and BIOASTER announced having officialized a broad research agreement for the development of diagnostic and management innovation for infectious diseases. This relationship will harness BIOASTER’s scientific and technical expertise, including technology platforms, to support Debiopharm’s breakthrough research programs. Their development efforts are expected to accelerate projects towards industrial product readiness.
The initial planned project is aimed at exploring further developments of FibroTrap, an easy-to-use sample preparation method for the rapid diagnosis of hard to detect bacteria. Debiopharm’s unique sample preparation technology has already demonstrated excellent sensitivity in the detection of bacteria and yeasts in blood stream infections with the potential to shorten the turn-around-time between sample collection to results from 1-3 days, seen with standard blood culture methods to about 3 hours, including pathogen identification.
“We ae very enthusiastic and proud to work with Debiopharm to advance innovation for patients. This collaboration will bring together complementary expertise of both parties for accelerating this innovation towards industrial product development in the field of Infectious Diseases and Microbiology.” Nathalie Garçon, CEO & CSO of BIOASTER
“This agreement with BIOASTER was initiated in light of our shared, patient-focused ambitions such as improving the speed of quality bedside diagnosis and developing innovation solutions to fight anti-microbial resistance.” Bertrand Ducrey, CEO, Debiopharm International S.A.
www.debiopharm.com / @DebiopharmNews at http://twitter.com/DebiopharmNews
www.bioaster.org / @BIOASTER at http://twitter.com/BIOASTER